Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights GLOBE NEWSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on TNXP
    Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
    6:59a ET October 15 '26 GlobeNewswire
    Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026GlobeNewswireOctober 15, 2026

    BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, "Vectored Vaccine Platforms: From Design to Improving Efficacy," at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.

    TNX-801 Presentation DetailsTitle: TNX-801 Vaccine Platform Safety and EfficacyDate & Time: Oct. 21, 2026, 1:15 p.m. CESTSession Category: Emerging & Infectious DiseasesPresenter: Farooq Nasar, Ph.D., MPH, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

    Other Session DetailsTitle: Working Group: Vectored Vaccine Platforms: From Design to Improving EfficacyDate & Time: Oct 20, 2026, 11:30 a.m. CESTSession Category: Working GroupsPresenters: Sina Bavari, Ph.D., Executive Vice President, Infectious Disease, RDC, Tonix Pharmaceuticals; Gabriella Worwa, DVM, Ph.D., Study Director, RDC, Tonix Pharmaceuticals; Matilu Mwau, Senior Principal Clinical Research Scientist, Professor of Infectious Diseases, Kenya Medical Research Institute (KEMRI)

    About TNX-801TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine platform based on horsepox in pre-clinical development to prevent mpox, smallpox, and other emerging infectious diseases. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance of an Investigational New Drug Application (IND). TNX-801 is in the pre-IND stages of development.

    Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA(R) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) (sumatriptan injection 3 mg) and Tosymra(R) (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com.

    *Tonix's product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

    Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

    Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA(R) and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Investor ContactsDeborah ElsonTonix Pharmaceuticalsdeborah.elson@tonixpharma.cominvestor.relations@tonixpharma.com

    Brian Korbastr partners(917) 653-5122brian.korb@astrpartners.com

    Media ContactsAndrea CohenSam Brown Inc.(917) 209-7163andreacohen@sambrown.com

    COMTEX_494285064/2010/2026-10-15T06:59:15

    BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, "Vectored Vaccine Platforms: From Design to Improving Efficacy," at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.

    TNX-801 Presentation DetailsTitle: TNX-801 Vaccine Platform Safety and EfficacyDate & Time: Oct. 21, 2026, 1:15 p.m. CESTSession Category: Emerging & Infectious DiseasesPresenter: Farooq Nasar, Ph.D., MPH, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

    Other Session DetailsTitle: Working Group: Vectored Vaccine Platforms: From Design to Improving EfficacyDate & Time: Oct 20, 2026, 11:30 a.m. CESTSession Category: Working GroupsPresenters: Sina Bavari, Ph.D., Executive Vice President, Infectious Disease, RDC, Tonix Pharmaceuticals; Gabriella Worwa, DVM, Ph.D., Study Director, RDC, Tonix Pharmaceuticals; Matilu Mwau, Senior Principal Clinical Research Scientist, Professor of Infectious Diseases, Kenya Medical Research Institute (KEMRI)

    About TNX-801TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine platform based on horsepox in pre-clinical development to prevent mpox, smallpox, and other emerging infectious diseases. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance of an Investigational New Drug Application (IND). TNX-801 is in the pre-IND stages of development.

    Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA(R) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) (sumatriptan injection 3 mg) and Tosymra(R) (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com.

    *Tonix's product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

    Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

    Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA(R) and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Investor ContactsDeborah ElsonTonix Pharmaceuticalsdeborah.elson@tonixpharma.cominvestor.relations@tonixpharma.com

    Brian Korbastr partners(917) 653-5122brian.korb@astrpartners.com

    Media ContactsAndrea CohenSam Brown Inc.(917) 209-7163andreacohen@sambrown.com

    COMTEX_494285064/2010/2026-10-15T06:59:15

    Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcar...
    7:00a ET November 4 '26 GLOBE NEWSWIRE
    Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive V...
    7:00a ET November 2 '26 GLOBE NEWSWIRE
    Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstra...
    7:00a ET October 27 '26 GLOBE NEWSWIRE
    Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results ...
    7:00a ET October 26 '26 GLOBE NEWSWIRE
    Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMY...
    7:00a ET October 19 '26 GLOBE NEWSWIRE
    Tonix Pharmaceuticals Announces Presentations at World Vaccine Congre...
    6:59a ET October 15 '26 GlobeNewswire
    Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer A...
    10:52p ET September 22 '26 GlobeNewswire
    Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commerci...
    6:59a ET September 8 '26 GlobeNewswire
    Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthca...
    7:00a ET September 2 '26 GlobeNewswire

    Market data provided by News provided by